Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1 ...

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort ...

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on March 4, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 ...

PHILADELPHIA, PA — Will Chou, M.D., the president and CEO of Passage Bio (NASDAQ: PASG), is set to present at Chardan’s 8th Annual Genetic Medicines Conference on October 1, 2024. This notable ...

Get the detailed quarterly/annual income statement for Passage Bio, Inc. (PASG). Find out the revenue, expenses and profit or loss over the last fiscal year.